KRAS and colorectal carcinoma: KRAS mutations, particularly at codon 12, are observed in approximately 40–50% of CRC patients and are widely recognized as a major mechanism of resistance to antiepidermal growth factor receptor therapies such as cetuximab and panitumumab [44].